Although there are no biomarkers in clinical use for SAC-abrogating drugs, Myc amplification and/or overexpression and RB1 loss have been suggested as predictors of sensitivity to AURKBi, particularly in SCLC [17, 40, 44]. This evidence concerns the gene MYC and small cell lung carcinoma.